TURN-COVID: Dutch cohort study evaluating the use of neutralizing monoclonal SARS-CoV-2 antibodies

Key facts

Disease
COVID-19
Start & end year
2021
2025
Funder
Netherlands Organisation for Health Research and Development (ZonMW)
Principal Investigator
dr WJ. prof Wiersinga MD PhD
Research Location
N/A
Lead Research Institution
Amsterdam UMC Locatie VUmc
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

Despite vaccination, some patients with a compromised immune system have an increased risk of Covid-19 with a serious course. The use of neutralizing monoclonal SARS-CoV-2 antibodies is a breakthrough in the treatment of Covid-19 for this patient group. This new therapy prevents Covid-19 related hospitalizations and deaths, provided the drug is given early in the disease process. This could substantially reduce the pressure on hospitals. Goal TURN-COVID is a national cohort study focused on the use of neutralizing monoclonal SARS-CoV-2 antibodies as therapy against Covid-19 in high-risk patients. The aim of the study is to map the use, effectiveness, safety and costs of the different antibodies. In addition, a national platform is being created to evaluate future unregistered treatments for Covid-19.

7 Publications linked via Europe PMC

Last Updated:3 days ago

View all publications at Europe PMC

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study.

A Longitudinal Description of the Health-Related Quality of Life Among Individuals at High Risk After SARS-CoV-2 Infection: A Dutch Multicenter Observational Cohort Study.

Proteomic profiling of neutrophils and plasma in community-acquired pneumonia reveals crucial proteins in diverse biological pathways linked to clinical outcome.

A Robust Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T- and B-Cell Response Is Associated With Early Viral Clearance in SARS-CoV-2 Omicron-Infected Immunocompromised Individuals.

Host Response Changes and Their Association with Mortality in COVID-19 Patients with Lymphopenia.

Age-related changes in plasma biomarkers and their association with mortality in COVID-19.

Authors
Michels EHA, Appelman B, de Brabander J, van Amstel RBE, Chouchane O, van Linge CCA, Schuurman AR, Reijnders TDY, Sulzer TAL, Klarenbeek AM, Douma RA, Amsterdam UMC COVID-19 Biobank Study Group, Bos LDJ, Wiersinga WJ, Peters-Sengers H, van der Poll T, Amsterdam UMC COVID-19 Biobank Study Group, van Agtmael M, Algera AG, Appelman B, van Baarle F, Beudel M, Bogaard HJ, Bomers M, Bonta P, Bos L, Botta M, de Brabander J, de Bree G, de Bruin S, Bugiani M, Bulle E, Buis DTP, Chouchane O, Cloherty A, Dijkstra M, Dongelmans DA, Dujardin RWG, Elbers P, Fleuren L, Geerlings S, Geijtenbeek T, Girbes A, Goorhuis B, Grobusch MP, Hagens L, Hamann J, Harris V, Hemke R, Hermans SM, Heunks L, Hollmann M, Horn J, Hovius JW, de Jong HK, de Jong MD, Koning R, Lemkes B, Lim EHT, van Mourik N, Nellen J, Nossent EJ, Olie S, Paulus F, Peters E, Pina-Fuentes DAI, van der Poll T, Preckel B, Prins JM, Raasveld J, Reijnders T, de Rotte MCFJ, Schinkel M, Schultz MJ, Schrauwen FAP, Schuurman A, Schuurmans J, Sigaloff K, Slim MA, Smeele P, Smit M, Stijnis CS, Stilma W, Teunissen C, Thoral P, Tsonas AM, Tuinman PR, van der Valk M, Veelo DP, Volleman C, de Vries H, Vught LA, van Vugt M, Wouters D, Zwinderman AHK, Brouwer MC, Wiersinga WJ, Vlaar APJ, van de Beek D.
Publish Year
2023
Journal
The European respiratory journal
DOI
10.1183/13993003.00011-2023

View at Europe PMC

Real-world Evidence of the Effects of Novel Treatments for COVID-19 on Mortality: A Nationwide Comparative Cohort Study of Hospitalized Patients in the First, Second, Third, and Fourth Waves in the Netherlands.